ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 0922 • ACR Convergence 2024

    Generation and Pathophysiological Analysis of M694I Variant Knock-in Mice of Human MEFV Gene: Insights from Single-Cell RNA Sequencing

    Tomohiro Koga, Yoshika Tsuji and Atsushi Kawakami, Nagasaki University, Nagasaki, Japan

    Background/Purpose: The primary objective of this study was to generate knock-in mice with the M694I variant of the human MEFV gene, a critical variant in…
  • Abstract Number: 1704 • ACR Convergence 2024

    Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis

    Dimitrios Anastasios Palamidas1, Maria Papadaki2, Nikolaos Paschalidis3, Eleftherios Pavlos4, Loukas chatzis1, Ourania Argyropoulou5, Panagiota Palla5, Ioanna-Evdokia Galani6, Andreas Goules7, Evangelos Andreakos4 and Athanasios Tzioufas8, 1Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 2Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, 3Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, 4Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, 5Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, 6Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, 7GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, 8LAIKO HOSPITAL, Athens, Greece

    Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
  • Abstract Number: 2689 • ACR Convergence 2024

    Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

    Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
  • Abstract Number: 0246 • ACR Convergence 2024

    Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies

    Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
  • Abstract Number: 0934 • ACR Convergence 2024

    Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies

    Isak Tengesdal1, Carlo Marchetti1, Tim L.Th. Jansen2, Marc Y. Donath3, Naomi Schlesinger4 and Charles Dinarello1, 1University of Colorado, Denver, CO, 21VieCuri Medisch Centrum, Venlo, Netherlands, 3University of Basel, Basel, Switzerland, 4University of Utah, Salt Lake City, UT

    Background/Purpose: NLRP3 is emerging as an attractive upstream target of the pathway to down-modulate rather than to completely neutralize IL-1ß levels in both acute and…
  • Abstract Number: 1765 • ACR Convergence 2024

    CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling

    Susan Canny1, Hannah DeBerg2, Griffin Gessay2, Ailing Lu3, Mary Eckert4, Andrea La Bella5, Hayley Waterman2, Danish Nadeem2, Susan Shenoi6, Joyce Hui-Yuen7, Daniel Campbell2, Betsy Barnes8 and Jessica Hamerman2, 1University of Washington, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Northwell Health, Manhasset, NY, 4Seattle Children's Hospital, Seattle, WA, 5Cohen Children's Medical Center, Queens, NY, 6Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 7North Shore LIJ Health System, Great Neck, NY, 8Feinstein Institutes for Medical Science, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
  • Abstract Number: 0275 • ACR Convergence 2024

    Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation

    Sadiq Umar1 and Sriram Ravindran2, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois, Chicago

    Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
  • Abstract Number: 0941 • ACR Convergence 2024

    DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways

    Michal Segal Salto1, Rebecca Ross2, Steven Ferrara3, Kelvin Chan4, Elvira haimov5, Francesco Del Galdo6 and Kulveer Mankia6, 1DeepCure Inc., Tel Aviv, Israel, 2Medicine and Health, University of Leeds, Leeds, United Kingdom, 3DeepCure Inc., Boston, MA, 4DeepCure Inc., Texas, NV, 5DeepCure Inc., Los Angeles, CA, 6University of Leeds, Leeds, United Kingdom

    Background/Purpose: Bromodomain and Extra-Terminal domain (BET) family proteins (BRD2, BRD3, BRD4, and BRDT) control the transcription of a wide range of proinflammatory and immunoregulatory genes.…
  • Abstract Number: 1782 • ACR Convergence 2024

    DOCK2 Mutations and Hyper-Inflammatory Syndromes

    Randy Cron, Mingce Zhang and Prescott Atkinson, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal hyper-inflammatory complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous…
  • Abstract Number: 0327 • ACR Convergence 2024

    Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

    Samuel Govea-Peláez1, Beatriz Alcalá-Carmona2, Jennifer Balderas Miranda3, Yatzil Reyna-Juárez2, María José Ostos-prado2, Nancy R Mejía-Domínguez2, Guillermo Juarez-Vega4, Jiram Torres Ruiz5 and Diana Gomez-martin6, 1INCMNSZ, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Mexico, Federal District, Mexico, 6INCMNSZ, Mexico City, Federal District, Mexico

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
  • Abstract Number: 0955 • ACR Convergence 2024

    Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis

    Goncalo Boleto1, Anne Cauvet2, James Rose3, Lih-Yun Hsu3, Richard A. Miller3 and Yannick Allanore4, 1Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, 2Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, 3Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, 4Université Paris Cité, Paris, France

    Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
  • Abstract Number: 1799 • ACR Convergence 2024

    In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus

    Jia Xin Chow1, Rochelle Sherlock2, Taylah Bennett2, Eric Morand3 and Sarah Jones2, 1Monash University, Melbourne, Victoria, Australia, 2Monash University, Melbourne, Australia, 3School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: The strategy of inhibiting toll-like receptors (TLR) 7 and 8 is being evaluated in clinical trials in systemic lupus erythematosus (SLE) to assess its…
  • Abstract Number: 0342 • ACR Convergence 2024

    Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis

    Sung Ik Cho1, Miriam Kim2, Ju yeon Kim3, Jin Kyun Park4, Eun Young Lee5, eun Bong Lee6 and Jun Won park3, 1Seoul National University Hospital, Jongno-gu, Seoul-t'ukpyolsi, Republic of Korea, 2Seoul National University, Seoul, Republic of Korea, 3Seoul National University Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 4Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 53Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 6Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: To investigate whether serum levels of cytokine and chemokine can predict a treatment response in patients with idiopathic inflammatory myositis (IIM)Methods: This study included…
  • Abstract Number: 1132 • ACR Convergence 2024

    Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy

    Dylan Richards1, Marion Vetter1, Matthew Germinaro1, Bram Verstockt2, Raja Atreya3, Julián Panés4, Bruce E. Sands5, Brian G. Feagan6, Bradford McRae7, Daniel Cua1, Patrick Branigan1 and Tom C. Freeman1, 1Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, 2Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium, 3Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, 4Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, Barcelona, Spain, 5Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY, 6Alimentiv Inc, London, ON, Canada, London, ON, Canada, 7Janssen Research & Development, Cambridge, MA, USA, Cambridge, MA

    Background/Purpose: Combination induction therapy with guselkumab (GUS), an interleukin (IL)-23p19 subunit antagonist, and golimumab (GOL), a tumor necrosis factor (TNFα) antagonist, induced higher rates of…
  • Abstract Number: 1801 • ACR Convergence 2024

    Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus

    Tania Rowley1, Adnan R. Khan1, Laura McLaughlin1, Hannah Cherry1, Farnaz Fallah-Arani1, Yiannis Ioannou1, Debasish Pyne2 and Anthony Shock1, 1UCB Pharma, Slough, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 42
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology